Ozempic maker Novo Nordisk's board shaken up as directors quit

Novo Nordisk, the pharmaceutical company behind Wegovy and Ozempic, is undergoing a significant boardroom overhaul, with seven directors, including the chairman, departing due to a governance dispute with its majority shareholder, the Novo Nordisk Foundation. This extensive leadership change, driven by the Foundation's view that the company has been "too slow in recognising fundamental market changes" amid rising competition from rivals like Eli Lilly, follows recent profit warnings and a new CEO. The news led to a 1.7% dip in Novo Nordisk's shares, underscoring investor concerns regarding strategic agility and stability as the company faces increasing market pressures.

Analysis

Novo Nordisk is undergoing a significant boardroom overhaul, with seven directors, including the chairman, set to depart following an extraordinary investor meeting in November. This extensive clear-out stems from a governance dispute between the board and its majority shareholder, the non-profit Novo Nordisk Foundation, which holds 28.1% of shares but commands a three-quarter share of voting rights. The market reacted negatively, with shares dipping 1.7% on the news, reflecting concerns over leadership stability.

The Novo Nordisk Foundation, asserting the company has been "too slow in recognising fundamental market changes," successfully pushed for a more extensive reconfiguration than initially proposed by the outgoing board. Lars Rebien Sorensen, the Foundation's chairman and former pharma CEO, is slated to replace the current chairman, indicating a direct and powerful intervention in corporate strategy and leadership.

This governance shift occurs amidst a challenging period for Novo Nordisk, which recently welcomed a new CEO in August, announced 9,000 layoffs in September, and issued profit warnings for the third time this year. Increased competition from US rivals, notably Eli Lilly, has eroded its valuation and pressured its previously robust profit growth forecasts, despite the widespread adoption of Wegovy and Ozempic.

The Foundation's decisive action underscores a critical juncture for the company, signaling an aggressive push for strategic agility and a potential re-evaluation of its market approach. Investors should closely monitor the new leadership's ability to navigate intense competition and stabilize financial performance.

Key Decisions for Investors

• Monitor the strategic direction and operational execution under the new leadership, particularly regarding competitive responses to Eli Lilly and future profit guidance.
• Evaluate the long-term implications of the Novo Nordisk Foundation's increased governance intervention on corporate autonomy and innovation.
• Assess the company's ability to stabilize its profit growth forecast and regain market share in the highly competitive weight-loss and diabetes drug markets.